Internal Medicine
RSSArticles
-
How Many Steps a Day Will Improve Patients’ Longevity?
A systematic review and meta-analysis of studies of the association of step counts and cadence with all-cause mortality and cardiovascular events showed the benefits in these outcomes are statistically significant, at about 2,600 steps/day and peak at about 8,000 steps/day. Also, faster step cadence augments these benefits.
-
Aberrant Conduction?
How should one interpret the ECG in the figure? Is the rhythm most likely to be a re-entry supraventricular tachycardia with aberrant conduction?
-
Momelotinib Tablets (Ojjaara)
Momelotinib can be prescribed to treat intermediate- or high-risk myelofibrosis.
-
Major Cardiovascular Event Risk Reduction with Pitavastatin in Patients Living with HIV
Among participants living with HIV who are at low-to-moderate risk for cardiovascular disease, those who received pitavastatin were 35% less likely to experience a major adverse cardiovascular event over a follow-up of approximately five years vs. those who received placebo.
-
The Hemodynamic Effects of an SGLT2 Inhibitor in Heart Failure with Preserved Ejection Fraction
The authors of a small, placebo-controlled study of 24 weeks of dapagliflozin therapy in patients with heart failure with preserved ejection fraction reported reductions in pulmonary capillary wedge pressure, which may explain the reductions in heart failure hospitalizations or cardiovascular death in larger randomized outcome trials.
-
Biomarker Profiles of Those Living to Age 100 Years
Among 1,224 participants who lived to their 100th birthday, there were higher levels of total cholesterol and iron, and lower levels of glucose, creatinine, uric acid, liver enzymes, and alkaline phosphatase compared with non-centenarians. These differences were seen as early as age 65 years.
-
Canakinumab Injection (Ilaris)
Canakinumab can be prescribed to adults with gout in whom nonsteroidal anti-inflammatory drugs and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.
-
An RNA Shot for Hypertension?
One dose of a new RNA-based drug administered by subcutaneous injection, which blocks hepatic angiotensinogen production, resulted in sustained reductions in blood pressure in patients with hypertension for up to 24 weeks without any serious adverse effects.
-
Is the Combination of a GLP-1 Agonist and a SGLT2 Inhibitor Safe?
An analysis of the Harmony Outcomes study and a meta-analysis combining it with the AMPLITUDE-O study of the addition of a glucagon-like peptide 1 receptor agonist (GLP-1 RA) in a subgroup of type 2 diabetes patients on baseline sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy has shown that major adverse cardiovascular events are reduced by GLP-1 RA, regardless of baseline SGLT2 use, and there was no difference in serious adverse events.
-
Treating Preclinical Alzheimer’s Disease
After studying an anti-amyloid antibody, solanezumab, researchers reported there was no benefit in reducing the likelihood of progression of cognitive impairment in patients with positive amyloid PET scans who started the trial cognitively unimpaired, compared to placebo.